ABOG | American Board of Obstetrics and Gynecology |
ABOUT | American BRCA Outcomes and Utilization of Testing [Patient-Powered Research Network] |
ACA | Patient Protection and Affordable Care Act |
ACMG | American College of Medical Genetics and Genomics |
ACOG | American Congress of Obstetricians and Gynecologists |
ACS | American College of Surgeons |
ACT | adoptive cell therapy |
AHRQ | Agency for Healthcare Research and Quality |
ASCO | American Society of Clinical Oncology |
BER | base excision repair |
BMI | body mass index |
BOT | borderline ovarian tumor |
BRCA | breast cancer genes 1 and 2 |
BSO | bilateral salpingo-oophorectomy |
BSOR | bilateral salpingectomy with ovarian retention |
CA-125 | cancer antigen 125 |
CAM | complementary and alternative medicine |
CCC | clear cell carcinoma |
CDC | Centers for Disease Control and Prevention |
CMS | Centers for Medicare & Medicaid Services |
CPTAC | Clinical Proteomic Tumor Analysis Consortium |
CT | computed tomography |
CTCAE | Common Terminology Criteria for Adverse Events |
CTEP | Cancer Therapy Evaluation Program |
D&I | dissemination and implementation |
DNA | deoxyribonucleic acid |
DoD | U.S. Department of Defense |
EBI | evidence-based intervention |
EC | endometrioid carcinoma |
EGFR | epidermal growth factor receptor |
EMT | epithelial to mesenchymal transition |
FDA | U.S. Food and Drug Administration |
FIGO | International Federation of Gynecology and Obstetrics |
FORCE | Facing Our Risk of Cancer Empowered |
FTE | fallopian tube epithelium |
GEMM | genetically engineered mouse model |
GH | growth hormone |
GOG | Gynecologic Oncology Group |
HBOC | hereditary breast and ovarian cancer [syndrome] |
HE-4 | human epididymis protein 4 |
HGSC | high-grade serous carcinoma |
HHS | U.S. Department of Health and Human Services |
HPV | human papillomavirus |
HR | homologous recombination |
IGF-1 | insulin-like growth factor 1 |
IOM | Institute of Medicine |
IP | intraperitoneal |
IrRC | immune-related response criteria |
IV | intravenous |
LBA | laboratory biomarker analysis |
LGSC | low-grade serous carcinoma |
MAPK | mitogen-activated protein kinase |
MC | mucinous carcinoma |
miR | microRNA |
MMS | multimodal screening |
MRI | magnetic resonance imaging |
NACT | neoadjuvant chemotherapy |
NCCN | National Comprehensive Cancer Network |
NCI | National Cancer Institute |
NGS | next-generation sequencing |
NHEJ | nonhomologous end joining |
NIH | National Institutes of Health |
NOCC | National Ovarian Cancer Coalition |
NRC | National Research Council |
NSGC | National Society of Genetic Counselors |
OC | oral contraceptive |
OCNA | Ovarian Cancer National Alliance |
OCRF | Ovarian Cancer Research Fund |
OCRP | Ovarian Cancer Research Program |
OCS | Office of Cancer Survivorship |
OSE | ovarian surface epithelium |
PARP | poly ADP ribose polymerase |
PCORI | Patient-Centered Outcomes Research Institute |
PCOS | polycystic ovarian syndrome |
PDS | primary debulking surgery |
PDX | patient-derived xenograft |
PFS | progression-free survival |
PID | pelvic inflammatory disease |
PLCO | prostate, lung, colorectal, and ovarian [cancer screening trial] |
PPC | primary palliative care |
PRO | patient-reported outcome |
QOL | quality of life |
RCT | randomized controlled trial |
RMI | Risk of Malignancy Index |
RNA | ribonucleic acid |
ROCA | risk of ovarian cancer algorithm |
ROMA | risk of ovarian malignancy algorithm |
RRSO | risk-reducing salpingo-oophorectomy |
SBT | serous borderline tumor |
SEER | surveillance, epidemiology, and end results |
SGO | Society of Gynecologic Oncology |
SNP | single-nucleotide polymorphism |
SPC | specialty palliative care |
SPORE | Specialized Program of Research Excellence |
STIC | serous tubal intraepithelial carcinoma |
TCGA | The Cancer Genome Atlas |
TVU | transvaginal ultrasound |
UKCTOCS | United Kingdom Collaborative Trial of Ovarian Cancer Screening |
USPSTF | U.S. Preventive Services Task Force |
VEGF | vascular endothelial growth factor |
VEGFR | vascular endothelial growth factor receptor |
WOO | window of opportunity |